Oxford Biomedica and Santen enter R&D collaboration and Option & Licence Agreement for development of gene therapy vectors for inherited retinal disease
Oxford, UK and Osaka, Japan – Oxford Biomedica plc (LSE:OXB) a leading gene and cell therapy group, and Santen Pharmaceutical Co., Ltd., the market leader for prescription ophthalmic pharmaceuticals in Japan with a global presence in over 60 countries, today announced that they have entered into an R&D collaboration and Option & Licence Agreement to research and develop gene therapy products for the treatment of inherited retinal disease. Inherited retinal diseases are a group of rare disorders caused by one of more than 260 different genes, where mutation results in vision loss or blindness1.
Inherited retinal diseases are ideal candidates for gene therapy because many of the responsible genetic mutations have already been identified1,2. In addition, the eye is a readily accessible organ conducive to direct delivery of gene therapy vectors to the diseased tissue. A key advantage with lentiviral vectors is their ability to deliver large therapeutic genes, which is technically challenging with other vector systems3.
The aim of the R&D collaboration is to generate pre-clinical proof of concept to treat inherited retinal disease with lentiviral vectors developed and manufactured by OXB. The collaboration includes a licence to use OXB’s LentiVector® platform and access to its industrial-scale manufacturing capabilities. Oxford Biomedica is entitled to an undisclosed milestone payment on exercise of the option to the LentiVector® platform as well as development milestones and up to a 10% royalty on net sales. Santen has worldwide commercial rights to the programme, while OXB retains an option to co-fund and participate in development and commercialisation in the US and Europe.
John Dawson, Chief Executive Officer of Oxford Biomedica, said:
“We are delighted to have formed our first collaboration in Japan. Santen is a leading, multi-national ophthalmology company developing innovative gene therapy products for the treatment of significant inherited retinal disease affecting patients with few or no therapy options. We believe that our LentiVector® platform is particularly well-suited to the delivery of large genes to the eye. We look forward to working together with Santen in a true partnership that will bring to bear our respective capabilities in gene therapy vectors and inherited retinal diseases to maximise the value of this important R&D programme.”
Naveed Shams, M.D., Ph.D., Chief Scientific Officer and Head of Global R&D at Santen, said :
“We are excited to partner with Oxford Biomedica and leverage their lentiviral vector platform to develop innovative therapeutics for inherited retinal disease. A gene therapy approach to treating inherited retinal diseases will allow Santen to meet the needs of patients suffering from inherited retinal dystrophies. This important collaboration builds on Santen’s ongoing research efforts as part of the CiCLE Programme from the Japan Agency for Medical Research and Development, and further strengthens our commitment to addressing challenges in ophthalmic care.”
- Source: US National Library of Medicine National Institutes of Health
Translational Vision & Science Technology https://www.ncbi.nlm.nih.gov/pmc/articles/PMC6052953/ [last accessed September 2019]
- Source: American Society of Gene & Cell Therapy
Inherited Retinal Diseases https://www.asgct.org/education/inherited-retinal-diseases[last accessed September 2019]
- Source: Gene Therapy Net.com
Lentiviral Vectors http://www.genetherapynet.com/viral-vector/lentiviruses.html [last accessed September 2019]
Job code: NP-SANTEN-EMEA-0120
Date of preparation: August 2019